Share:
Beacon (NASDAQ:BECN) (the Company ) announced today the appointment of Jonathan S. Bennett as Executive Vice President and Chief Commercial Officer (CCO). Mr. Bennett will join Beacon in this newly created role on June 1, 2021 and be responsible for the Company s integrated go-to-market strategy comprising selling excellence, category management, marketing, pricing, and supply chain.
Prior to joining Beacon, Mr. Bennett served as Executive Vice President, Merchandising and Supply Chain at Total Wine & More, the country s largest independent retailer of beverage alcohol, since 2016. There he was accountable for the product merchandising, market management, supply chain, pricing, and assortment planning functions. During this period, Total Wine doubled in total sales, launched hundreds of innovative new brands and implemented a new pricing system. From 2013 to 2016, he served as Chief Merchandising Officer of Interline Brands, a $2 billion facilities MRO business, where he le
Grab the Rally Towel! Pittsburgh Custodian Crowned 2021 Cintas Custodian of the Year streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Published: May 03, 2021
LONDON (BUSINESS WIRE) Gyroscope Therapeutics Holdings plc (“Gyroscope”), a clinical-stage gene therapy company focused on treating diseases of the eye, today announced that it has launched the roadshow for its initial public offering in the United States of up to 6,750,000 American Depositary Shares (“ADSs”) representing 6,750,000 ordinary shares. The initial public offering price is currently expected to be between $20.00 and $22.00 per ADS, which would result in an approximate total offering size of between $135.0 million and $148.5 million, before underwriting discounts and commissions. Gyroscope also expects to grant to the underwriters a 30-day option to purchase up to an additional 1,012,500 ADSs at the initial public offering price, less underwriting discounts and commissions. All ADSs to be sold in the proposed offering will be sold by Gyroscope. Gyroscope has applied to list its ADSs on the Nasdaq Global Select Market under the
May
4
, 2021 – ObsEva SA (NASDAQ:OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women s reproductive health, today announced that it has completed enrollment for the Phase 3 EDELWEISS 3 trial of Yeslty® for patients with moderate to severe endometriosis-associated pain (EAP). Enrollment completion is an important milestone, and data from the primary endpoint readout are expected in Q4 2021. Endometriosis is an emotionally and physically painful condition that affects approximately 176 million women worldwide and can be debilitating for many women. We continue to be in need of alternative treatment options that improve quality of life, said Jacques Donnez, M.D., Ph.D., Distinguished Professor of Obstetrics and Gynecology at the Catholic University of Louvain, Belgium. The Phase 2b EDELWEISS data underscored Yselty s potential to address this critical unmet need while offering unique dosing options. Importantly, linza